RECRUITING

A Brief Intervention for Cannabis Use

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to compare two brief interventions targeting potentially problematic cannabis use in emerging adults (ages 18-25). Brief interventions are two 40-50 minute sessions separated by 1 week. Eligible emerging adults will complete a detailed cannabis assessment (biological and self-report), followed by one of the two brief interventions, and three follow-up assessments: one immediately after the second session and at 1- and 3-months post-intervention. Assignment to the brief intervention is random. Salivary samples will be collected at baseline, post-intervention, and both follow-ups, for a total of 4 samples, to be tested for tetrahydrocannabinol (THC) and cannabidiol (CBD).

Official Title

Development of a Novel Cannabis Brief Intervention for Frequently-Using Emerging Adults: Pilot Randomized Trial

Quick Facts

Study Start:2024-10-18
Study Completion:2029-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06395389

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 25 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ages 18-25
  2. * Self-Report report cannabis use on at least 20 days of the past 30 days.
  3. * Completion of an Intake Visit (PRO #94743) in the past 30 days
  4. * Submit a positive urine cannabinoid test during the Intake Visit
  1. * Currently engaged in substance use treatment for any type of substance use
  2. * Severe alcohol use disorder or presence of any substance use disorder (SUD) requiring a higher level of care
  3. * Significant or acutely unstable medical or psychiatric problems (i.e., psychosis, mania) that would contraindicate research procedures, interfere with safety, compromise data integrity, or preclude consistent study participation
  4. * Significant risk of suicide or homicide

Contacts and Locations

Study Contact

Kathryn Gex, Ph.D.
CONTACT
(843) 792-4904
soltisk@musc.edu

Principal Investigator

Kathryn Gex, Ph.D.
PRINCIPAL_INVESTIGATOR
Medical University of South Carolina

Study Locations (Sites)

Medical University of South Carolina
Charleston, South Carolina, 29425
United States

Collaborators and Investigators

Sponsor: Medical University of South Carolina

  • Kathryn Gex, Ph.D., PRINCIPAL_INVESTIGATOR, Medical University of South Carolina

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-18
Study Completion Date2029-05

Study Record Updates

Study Start Date2024-10-18
Study Completion Date2029-05

Terms related to this study

Keywords Provided by Researchers

  • Early intervention
  • Emerging adults

Additional Relevant MeSH Terms

  • Cannabis Use Disorder